Compare WEX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEX | ORKA |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.4B |
| IPO Year | 2004 | 1997 |
| Metric | WEX | ORKA |
|---|---|---|
| Price | $181.09 | $106.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $202.09 | $156.17 |
| AVG Volume (30 Days) | 602.1K | ★ 994.1K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.93 | N/A |
| EPS | ★ 9.20 | N/A |
| Revenue | ★ $2,660,800,000.00 | N/A |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $2.45 | N/A |
| P/E Ratio | $19.49 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $125.29 | $25.23 |
| 52 Week High | $203.99 | $115.52 |
| Indicator | WEX | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 67.48 |
| Support Level | $148.03 | $83.25 |
| Resistance Level | $189.61 | $115.52 |
| Average True Range (ATR) | 7.00 | 5.87 |
| MACD | -0.58 | 1.30 |
| Stochastic Oscillator | 32.27 | 70.58 |
WEX Inc is a commerce platform that provides seamlessly embedded, personalized payments solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Its prime end market is the United States of America.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.